These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 36565681)

  • 1. Generation of human induced pluripotent stem cell lines with HMOX1 promoter polymorphism and CRISPR/Cas9-mediated deletion of exon 50 of DMD gene.
    Polak K; Stępniewski J; Ścieżyńska A; Podgórska A; Dulak J; Florczyk-Soluch U
    Stem Cell Res; 2023 Feb; 66():103004. PubMed ID: 36565681
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Single CRISPR-Cas9 Deletion Strategy that Targets the Majority of DMD Patients Restores Dystrophin Function in hiPSC-Derived Muscle Cells.
    Young CS; Hicks MR; Ermolova NV; Nakano H; Jan M; Younesi S; Karumbayaram S; Kumagai-Cresse C; Wang D; Zack JA; Kohn DB; Nakano A; Nelson SF; Miceli MC; Spencer MJ; Pyle AD
    Cell Stem Cell; 2016 Apr; 18(4):533-40. PubMed ID: 26877224
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Heme Oxygenase-1 Influences Satellite Cells and Progression of Duchenne Muscular Dystrophy in Mice.
    Pietraszek-Gremplewicz K; Kozakowska M; Bronisz-Budzynska I; Ciesla M; Mucha O; Podkalicka P; Madej M; Glowniak U; Szade K; Stepniewski J; Jez M; Andrysiak K; Bukowska-Strakova K; Kaminska A; Kostera-Pruszczyk A; Jozkowicz A; Loboda A; Dulak J
    Antioxid Redox Signal; 2018 Jul; 29(2):128-148. PubMed ID: 29669436
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Precise correction of the dystrophin gene in duchenne muscular dystrophy patient induced pluripotent stem cells by TALEN and CRISPR-Cas9.
    Li HL; Fujimoto N; Sasakawa N; Shirai S; Ohkame T; Sakuma T; Tanaka M; Amano N; Watanabe A; Sakurai H; Yamamoto T; Yamanaka S; Hotta A
    Stem Cell Reports; 2015 Jan; 4(1):143-154. PubMed ID: 25434822
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Restoration of Dystrophin Protein Expression by Exon Skipping Utilizing CRISPR-Cas9 in Myoblasts Derived from DMD Patient iPS Cells.
    Ifuku M; Iwabuchi KA; Tanaka M; Lung MSY; Hotta A
    Methods Mol Biol; 2018; 1828():191-217. PubMed ID: 30171543
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CRISPR/Cas9-generated mouse model of Duchenne muscular dystrophy recapitulating a newly identified large 430 kb deletion in the human
    Egorova TV; Zotova ED; Reshetov DA; Polikarpova AV; Vassilieva SG; Vlodavets DV; Gavrilov AA; Ulianov SV; Buchman VL; Deykin AV
    Dis Model Mech; 2019 Apr; 12(4):. PubMed ID: 31028078
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Creation of a Novel Humanized Dystrophic Mouse Model of Duchenne Muscular Dystrophy and Application of a CRISPR/Cas9 Gene Editing Therapy.
    Young CS; Mokhonova E; Quinonez M; Pyle AD; Spencer MJ
    J Neuromuscul Dis; 2017; 4(2):139-145. PubMed ID: 28505980
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CRISPR-Cas9 corrects Duchenne muscular dystrophy exon 44 deletion mutations in mice and human cells.
    Min YL; Li H; Rodriguez-Caycedo C; Mireault AA; Huang J; Shelton JM; McAnally JR; Amoasii L; Mammen PPA; Bassel-Duby R; Olson EN
    Sci Adv; 2019 Mar; 5(3):eaav4324. PubMed ID: 30854433
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Correction of Three Prominent Mutations in Mouse and Human Models of Duchenne Muscular Dystrophy by Single-Cut Genome Editing.
    Min YL; Chemello F; Li H; Rodriguez-Caycedo C; Sanchez-Ortiz E; Mireault AA; McAnally JR; Shelton JM; Zhang Y; Bassel-Duby R; Olson EN
    Mol Ther; 2020 Sep; 28(9):2044-2055. PubMed ID: 32892813
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A novel human muscle cell model of Duchenne muscular dystrophy created by CRISPR/Cas9 and evaluation of antisense-mediated exon skipping.
    Shimo T; Hosoki K; Nakatsuji Y; Yokota T; Obika S
    J Hum Genet; 2018 Mar; 63(3):365-375. PubMed ID: 29339778
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Precise correction of Duchenne muscular dystrophy exon deletion mutations by base and prime editing.
    Chemello F; Chai AC; Li H; Rodriguez-Caycedo C; Sanchez-Ortiz E; Atmanli A; Mireault AA; Liu N; Bassel-Duby R; Olson EN
    Sci Adv; 2021 Apr; 7(18):. PubMed ID: 33931459
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Amelioration of intracellular Ca
    Sato M; Shiba N; Miyazaki D; Shiba Y; Echigoya Y; Yokota T; Takizawa H; Aoki Y; Takeda S; Nakamura A
    Biochem Biophys Res Commun; 2019 Nov; 520(1):179-185. PubMed ID: 31585729
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vivo genome editing in mouse restores dystrophin expression in Duchenne muscular dystrophy patient muscle fibers.
    Chen M; Shi H; Gou S; Wang X; Li L; Jin Q; Wu H; Zhang H; Li Y; Wang L; Li H; Lin J; Guo W; Jiang Z; Yang X; Xu A; Zhu Y; Zhang C; Lai L; Li X
    Genome Med; 2021 Apr; 13(1):57. PubMed ID: 33845891
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CRISPR/Cas9 editing of directly reprogrammed myogenic progenitors restores dystrophin expression in a mouse model of muscular dystrophy.
    Domenig SA; Bundschuh N; Lenardič A; Ghosh A; Kim I; Qabrati X; D'Hulst G; Bar-Nur O
    Stem Cell Reports; 2022 Feb; 17(2):321-336. PubMed ID: 34995499
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Generation and characterization of an induced pluripotent stem cell line (ZSYYDNi001-A) from a patient with Duchenne muscular dystrophy carrying exon 51 deletion in the DMD gene.
    Wang L; Li H; Li Y; Xu M; Lin J; Liao Z; Pei Z; Zhang C
    Stem Cell Res; 2021 Oct; 56():102553. PubMed ID: 34619646
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Absence of full-length dystrophin impairs normal maturation and contraction of cardiomyocytes derived from human-induced pluripotent stem cells.
    Pioner JM; Guan X; Klaiman JM; Racca AW; Pabon L; Muskheli V; Macadangdang J; Ferrantini C; Hoopmann MR; Moritz RL; Kim DH; Tesi C; Poggesi C; Murry CE; Childers MK; Mack DL; Regnier M
    Cardiovasc Res; 2020 Feb; 116(2):368-382. PubMed ID: 31049579
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutic Exon Skipping Through a CRISPR-Guided Cytidine Deaminase Rescues Dystrophic Cardiomyopathy in Vivo.
    Li J; Wang K; Zhang Y; Qi T; Yuan J; Zhang L; Qiu H; Wang J; Yang HT; Dai Y; Song Y; Chang X
    Circulation; 2021 Nov; 144(22):1760-1776. PubMed ID: 34698513
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Full-Length Dystrophin Restoration via Targeted Exon Addition in DMD-Patient Specific iPSCs and Cardiomyocytes.
    Xiao R; Zhou M; Wang P; Zeng B; Wu L; Hu Z; Liang D
    Int J Mol Sci; 2022 Aug; 23(16):. PubMed ID: 36012442
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Restoring Dystrophin Expression with Duchenne Muscular Dystrophy Exon 45 Skipping in Induced Pluripotent Stem Cell-Derived Cardiomyocytes.
    Sato M; Shiba N; Miyazaki D; Shiba Y; Nakamura A
    Methods Mol Biol; 2023; 2587():141-151. PubMed ID: 36401028
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gene editing of Duchenne muscular dystrophy using biomineralization-based spCas9 variant nanoparticles.
    Li S; Du M; Deng J; Deng G; Li J; Song Z; Han H
    Acta Biomater; 2022 Dec; 154():597-607. PubMed ID: 36243370
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.